Plitidepsin is an antitumour agent of marine origin targeting EEF1A2 that has completed Phase 3 clinical trials for multiple myelomas.52,53 Metarrestin interacts with EEF1A2 to disrupt the perinucleolar compartment (PNC), and inhibits invasive ability of pancreatic cancer cells.54 Overexpression of eEF1A2 was associated with metastasis and poor prognosis of LUAD patients; hence, EEF1A2 is a potential target for the treatment of aggressive LUAD. The gene discussed is EEF1A2; the disease is plasma cell myeloma.